Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR

Basit Öğe Kaydı
dc.authorid0000-0003-0268-9641
dc.authorid0000-0001-8923-8709
dc.authorid0000-0002-7280-5137
dc.authorid0000-0002-1574-2053
dc.authorid0000-0002-3895-1923
dc.authorid0000-0002-6335-5250
dc.authorid0000-0002-0933-7852
dc.authorid0000-0002-4576-128X
dc.contributor.authorÖz, Ahmet
dc.contributor.authorToprak, Kenan
dc.contributor.authorAydın, Ertan
dc.contributor.authorSaraç, İbrahim
dc.contributor.authorDoğduş, Mustafa
dc.contributor.authorOpan, Selçuk
dc.contributor.authorYenerçağ, Mustafa
dc.contributor.authorİnci, Sinan
dc.date.accessioned2025-04-10T05:27:25Z
dc.date.available2025-04-10T05:27:25Z
dc.date.issued2024
dc.departmentTıp Fakültesi
dc.description.abstractDual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued. Objectives: The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study. Methods: A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%. Results: Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.
dc.identifier.doi10.36660/abc.20240202
dc.identifier.issue11
dc.identifier.scopus2-s2.0-85210826965
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.36660/abc.20240202
dc.identifier.urihttps://hdl.handle.net/20.500.12451/12993
dc.identifier.volume121
dc.identifier.wos001415844900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorİnci, Sinan
dc.institutionauthorid0000-0002-4576-128X
dc.language.isoother
dc.publisherSociedade Brasileira de Cardiologia
dc.relation.ispartofArquivos Brasileiros de Cardiologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDual Anti-Platelet Therapy
dc.subjectHemorrhage
dc.subjectThrombosis
dc.titleFixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR
dc.title.alternativeFixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
oz-ahmet-2024.pdf
Boyut:
556.01 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu